A Better Newspaper

## Overview US President Donald Trump signed an executive order directing his administration to speed up regulatory reviews of certain psychedelic drugs, including ibogaine, which has been embraced by combat veterans and conservative lawmakers despite carrying serious safety risks (SCMP, April 2026). ## Key Drug: Ibogaine Ibogaine is currently classified under the federal government's most restrictive Schedule I category for illegal, high-risk drugs (SCMP, April 2026). Despite this, it has attracted significant advocacy from veterans communities who report it as effective for treating PTSD and opioid addiction. The Trump administration has indicated it is taking steps to ease access to psychedelics that have already been designated as potential breakthroughs under existing FDA frameworks. ## Political Dynamics The executive order reflects an unusual bipartisan and cross-ideological coalition supporting psychedelic research reform, spanning veterans' advocates, libertarian-leaning conservatives, and progressive mental health reformers. Conservative lawmakers have reportedly championed ibogaine access specifically due to its reported efficacy for combat veterans (SCMP, April 2026). ## Regulatory Pathway The order focuses on accelerating existing FDA review processes rather than immediate rescheduling. The administration is reportedly working within the breakthrough therapy designation framework to create an expedited pathway (SCMP, April 2026). ## Legal and Business Implications - Potential Schedule I reclassification would open significant pharmaceutical and clinical research markets - Liability questions remain complex given ibogaine's documented cardiac risks - First-mover advantage for clinical trial operators and IP holders in the psychedelic therapeutics space - State-level legal frameworks (Oregon, Colorado) may interact with federal pathway changes ## Watching Brief - FDA formal response to the executive order and timeline for breakthrough designation reviews - Congressional legislation to codify rescheduling or expanded access - Clinical trial activity by pharmaceutical companies post-order - Safety regulatory framework development for ibogaine given cardiac risk profile